Revolution Medicines Inc. has been on a roll during the past year after entering into a partnership with Sanofi to develop its SHP2 inhibitor, buying Warp Drive Bio Inc. to bolster its cancer drug discovery capabilities and raising a $100m series C venture capital round to accelerate its development of small molecules that target various mutations in the RAS pathway downstream from SHP2.
[Sidebar#SC125510]






